A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
Status:
Terminated
Trial end date:
2018-01-12
Target enrollment:
Participant gender:
Summary
The purpose of the study is to collect and assess long term data on the safety, tolerability,
and efficacy of pridopidine in patients with Huntington's disease (HD).
Phase:
Phase 2
Details
Lead Sponsor:
Prilenia Teva Branded Pharmaceutical Products, R&D Inc.